English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

A20-Deficient Mast Cells Exacerbate Inflammatory Responses In Vivo

MPS-Authors
/persons/resource/persons78080

Heger,  Klaus
Schmidt-Supprian, Marc / Molecular Immunology and Signaltransduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78820

Vahl,  J. Christoph
Schmidt-Supprian, Marc / Molecular Immunology and Signaltransduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78648

Schmidt-Supprian,  Marc
Schmidt-Supprian, Marc / Molecular Immunology and Signaltransduction, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

journal.pbio.1001762.pdf
(Any fulltext), 3MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Heger, K., Fierens, K., Vahl, J. C., Aszodi, A., Peschke, K., Schenten, D., et al. (2014). A20-Deficient Mast Cells Exacerbate Inflammatory Responses In Vivo. PLOS BIOLOGY, 12(1): e1001762. doi:10.1371/journal.pbio.1001762.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0019-DBC6-F
Abstract
Mast cells are implicated in the pathogenesis of inflammatory and autoimmune diseases. However, this notion based on studies in mast cell-deficient mice is controversial. We therefore established an in vivo model for hyperactive mast cells by specifically ablating the NF-kappa B negative feedback regulator A20. While A20 deficiency did not affect mast cell degranulation, it resulted in amplified pro-inflammatory responses downstream of IgE/Fc epsilon RI, TLRs, IL-1R, and IL-33R. As a consequence house dust mite- and IL-33-driven lung inflammation, late phase cutaneous anaphylaxis, and collagen-induced arthritis were aggravated, in contrast to experimental autoimmune encephalomyelitis and immediate anaphylaxis. Our results provide in vivo evidence that hyperactive mast cells can exacerbate inflammatory disorders and define diseases that might benefit from therapeutic intervention with mast cell function.